Essential fatty acids as potential anti-inflammatory agents in the treatment of affective disorders

Inflammation in Psychiatry

Volumn 28, Issue , 2013, Pages 75-89

  Song, Cai ^a,b  

^a Chin Acad Eng Inst for the Dev of Endangered Medicinal Resources in Southwest China Guangxi Botanic Garden of Medicinal Plants   (China)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925694792     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000343970     Document Type: Chapter

References (77)

1. Song C, Wang H: Cyokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;9;35:760-768.
2. Song C: The effect of thymectomy and IL-1 on memory: implications for the relationship between immunity and depression. Brain Behav Immun 2002;16:557-568.
3. Song C, Zhao S: Omega-3 fatty acid eicosapentaenoic acid. A new treatment for psychiatric and neurodegenerative diseases: a review of clinical investigations. Expert Opin Investig Drugs 2007;16:1627-1638.
4. Madeline L, Joanna KS, Sidney HK: Inflammatory biomarkers in depression: an opportunityfor novel therapeutic interventions. Curr Psychiatry Rep 2011;13:316-320.
5. Carpenter LL, Gawuga CE, Tyrka AR, et al: Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology 2010;35:2617-2623.
6. Janelidze S, Mattei D, Westrin D, et al: Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun 2011;25: 335-339.
7. Lehto SM, Niskanen L, Miettola J, et al: Serum anti-inflammatory markers in general population subjects with elevated depressive symptoms. Neurosci Lett 2010;484:201-205.
8. Pavlović Z, Delić D, Marić NP, et al: Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study. Psychiatr Danub 2011;23: 370-377.
9. Friebe A, Horn M, Schmidt F, et al: Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma. Psychosomatics 2010;51:466-473.
10. Raison CL, Borisov AS, Majer M, et al: Activation of central nervous system inflammatory pathways by interferonalpha: relationship to monoamines and depression. Biol Psychiatry 2009;65: 296-303.
11. Kenis G, Prickaerts J, van Os J, et al: Depressive symptoms following interferon-α therapy: mediated by immune-induced reductions in brainderived neurotrophic factor? Int J Neuropsychopharmacol 2011;14:247-253.
12. Suvisaari J, Loo BM, Saarni SE, et al: Inflammation in psychotic disorders: a population-based study. Psychiatry Res 2011;189:305-311.
13. Hope S, Dieset I, Agartz I, et al: Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiat Res 2011;45:1608-1616.
14. Maes M: Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuro-Psychopharmacol Biol Psychiatr 2011;35:664-675.
15. Drexhage RC, Hoogenboezem TH, Versnel MA, et al: The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav Immun 2011;25:1206-1213.
16. Weigelt K, Carvalho LA, Drexhage RC, et al: TREM-1 and DAP12 expression in monocytes of patients with severe psychiatric disorders. EGR3, ATF3 and PU.1 as important transcription factors. Brain Behav Immun 2011;25:1162-1169.
17. Tsai SY, Chen KP, Yang YY, et al: Activation of indices of cell-mediated immunity in bipolar mania. Biol Psychiatry 1999;45:989-994.
18. Lam RW, Song C, Yatham LN: Does neuroimmune dysfunction mediate seasonal mood changes in winter depression? Med Hypotheses 2004;63:567-573.
19. Song C, Lin A, Bonaccorso S, et al: The inflammatory response system and the tryptophan availability to the brain of patients with major depression and sleep disorders. J Affect Disord 1998; 49:211-219.
20. Leonard BE, Myint A: The psychoneuroimmunology of depression. Hum Psychopharmacol 2009;24:165-175.
21. Maes M, Leonard BE, Myint AM, et al: The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:702-721.
22. Raison CL, Dantzer R, Kelley KW, et al: CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 2010;15:393-403.
23. Gabbay V, Klein RG, Katz Y, et al: The possible role of the kynurenine pathway in adolescent depression with melancholic features. J Child Psychol Psychiatry 2010;51:935-943.
24. Kohl C, Walch T, Huber R, et al: Measurement of tryptophan, kynurenine and neopterin in women with and without postpartum blues. J Affect Disord 2005;86:135-142.
25. Laugeray A, Launay JM, Callebert J, et al: Peripheral and cerebral metabolic abnormalities of the tryptophankynurenine pathway in a murine model of major depression. Behav Brain Res 2010;210:84-91.
26. Severance EG, Dupont D, Dickerson FB, et al: Immune activation by casein dietary antigens in bipolar disorder. Bipol Dis 2010;12:834-842.
27. Ibrahim A, Mbodji K, Hassan A, et al: Anti-inflammatory and anti-angiogenic effect of long chain n-3 polyunsaturated fatty acids in intestinal microvascular endothelium. Clin Nutr 2011;30:678-687.
28. Ramakrishnan U: Fatty acid status and maternal mental health. Child Nutr 2011;7(suppl 2):99-111.
29. Gupta S, Knight AG, Gupta S, et al: Saturated long-chain fatty acids activate inflammatory signaling in astrocytes. J Neurochem 2012;120:1060-1071.
30. Weylandt KH, Chiu CY, Gomolka B, et al: Omega-3 fatty acids and their lipid mediators: Towards an understanding of resolvin and protectin formation omega-3 fatty acids and their resolvin/protectin mediators. Prostaglandins Other Lipid Mediat 2012;97:73-82.
31. Pascoe MC, Crewther SG, Carey LM, Crewther DP: What you eat is what you are. A role for polyunsaturated fatty acids in neuroinflammation induced depression? Clin Nutr 2011;30:407-415.
32. Freeman MP: Omega-3 fatty acids in major depressive disorder. J Clin Psychiatry 2009;70(suppl 5):7-11.
33. McNamara RK, Jandacek R, Rider T, et al: Selective deficits in erythrocyte docosahexaenoic acid composition in adult patients with bipolar disorder and major depressive disorder. J Affect Disord 2010;126:303-311.
34. Vines A, Delattre AM, Lima MM, et al: The role of 5-HT1A receptors in fish oilmediated increased BDNF expression in the rat hippocampus and cortex: a possible antidepressant mechanism. Neuropharmacology 2012;62:184-191.
35. Park Y, Moon HJ, Kim SH: n-3 polyunsaturated fatty acid consumption produces neurobiological effects associated with prevention of depression in rats after the forced swimming test. J Nutr Biochem 2012;23:924-928.
36. Miyazawa D, Yasui Y, Yamada K, et al: Biochemical responses to dietary α-linolenic acid restriction proceed differently among brain regions in mice. Biomed Res 2011;4:237-245.
37. Su KP: Biological mechanism of antidepressant effect of omega-3 fatty acids. How does fish oil act as a 'mindbody interface'? Neurosignals 2009;17: 144-152.
38. Chen CT, Liu Z, Ouellet M, Calon F, Bazinet RP: Rapid beta-oxidation of eicosapentaenoic acid in mouse brain: an in situ study. Protaglandins Leukot Essent Fatty Acids 2009;80:157-163.
39. Song C, Li XW, Leonard BE, Horrobin DF: Effects of dietary n-3 or n-6 fatty acids on interleukin-1beta-induced anxiety, stress and inflammatory responses in rats. J Lipid Res 2003;44:1984-1991.
40. Song C, Leonard BE, Horrobin DF: Ethyleicosapentaenoic acid but not soybean oil reverses central interleukin-1-induced anxiety, stress and inflammatory response in rats. Stress 2004;7:43-54.
41. Song C, Horrobin DF: Omega-3 fatty acid ethyl-eicosapentaenoic acid but not soybean oil attenuates memory impairment induced by central IL-1beta administration. J Lipid Res 2004;45:1112-1121.
42. Song C, Phillips AG, Leonard BE: Interleukin 1 beta enhances conditioned fear memory but impairs spatial learning in rats: possible involvement of glucocorticoids and monoamine function in the amygdala and hippocampus. Eur J Neurosci 2003;18:1739-1743.
43. Song C, Li XW, Leonard BE, Horrobin DF: Effects of dietary n-3 or n-6 fatty acids on interleukin-1beta-induced anxiety, stress and inflammatory responses in rats. J Lipid Res 2003;44:1984-1991.
44. Song C, Phillips AG, Leonard BE, Horrobin DF: Omega-3 fatty acid and RU 486 reverse IL-1-induced memory impairment in rats: a glucocorticoid involved mechanism. Mol Psychiatry 2004;9:630-638.
45. Song C, Leonard BE: Effects of acute and sub-chronic administration of Interleukin-1β on the behaviour, immune and neurotransmitter function in the rat. Pharmacopsychiatry 2006;39:88-99.
46. Song C, Li XW, Kang ZJ, Kadotomi Y: Omega-3 fatty acid ethyleicosapentaenoate attenuates IL-1-induced changes in dopamine and metabolites in the shell of the nucleus accumbens: involved with PLA2 activity and corticosterone secretion. Neuropsychophamacology 2007;32:736-744.
47. Song C, Zhang XY, Manku M: Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in a depression model olfactory bulbectomized rats: effects of chronic ethyl-eicosapentaenoate treatment. J Neurosci 2009;29:14-22.
48. Kou W, Luchtman D, Song C: Eicosapentaenoic acid (EPA) increases cell viability and expression of neurotrophin receptors in retinoic acid and brain-derived neurotrophic factor differentiated SHSY5Y cells. Eur J Nutr 2008;47:104-113.
49. Meng Q, Luchtman DW, El Bahh B, Zidichouski JA, Yang J, Song C: Ethyleicosapentaenoate modulates changes in neurochemistry and brain lipids induced by parkinsonian neurotoxin 1-methyl-4-phenylpyridinium in mouse brain slices. Eur J Pharmacol 2010;15; 649:127-134.
50. Taepavarapruk P, Song C: Reductions of acetylcholine release and nerve growth factor expression are correlated with memory impairment induced by interleukin-1β administrations: effects of omega-3 fatty acid EPA treatment. J Neurochem 2010;112:1054-1064.
51. Luchtman DW, Meng Q, Song C: Ethyleicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease. Behav Brain Res 2012;226:386-396.
52. Lu DY, Tsao YY, Leung YM, Su KP: Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia: implications of antidepressant effects for ω-3 fatty acids. Neuropsychopharmacology 2010;35:2238-2248.
53. Basselin M, Kim HW, Chen M, Ma K, et al: Lithium modifies brain arachidonic and docosahexaenoic metabolism in rat lipopolysaccharide model of neuroinflammation. J Lipid Res 2010; 51:1049-1056.
54. Peet M, Stokes C: Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs 2005;65:1051-1059.
55. Chiu CC, Frangou S, Chang CJ, et al: Associations between n-3 PUFA concentrations and cognitive function after recovery from late-life depression. Am J Clin Nutr 2012;95:420-427.
56. Frangou S, Lewis M, McCrone P: Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised doubleblind placebo-controlled study. Br J Psychiatry 2006;188:46-50.
57. Peet M, Murphy B, Shay J, et al: Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 1998;43:315-319.
58. Freeman MP, Hibbeln JR, Wisner KL, et al: Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 2006;67:1954-1967.
59. Hibbeln JR, Nieminen LR, Blasbalg TL, et al: Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. Am J Clin Nutr 2006;83: 1483S-1493S.
60. Frasure-Smith N, Lespérance F, Julien P: Major depression is associated with lower omega-3 fatty acid levels in patients with recent acute coronary syndromes. Biol Psychiatry 2004;55:891-896.
61. Colangelo LA, He K, Whooley MA, et al: Higher dietary intake of long-chain omega-3 polyunsaturated fatty acids is inversely associated with depressive symptoms in women. Nutrition 2009;25: 1011-1109.
62. Sinn N, Milte CM, Street SJ, et al: Effects of n-3 fatty acids, EPA . DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr 2011;20:1-12.
63. Lespérance F, Frasure-Smith N, St-André E, et al: The efficacy of omega-3 supplementation for major depression: a randomized controlled trial. J Clin Psychiatry 2011;72:1054-1062.
64. Rondanelli M, Giacosa A, Opizzi A, et al: Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: a double-blind, placebo-controlled, randomized clinical trial. J Am Coll Nutr 2010;29:55-64.
65. Sublette ME, Ellis SP, Geant AL, Mann JJ: Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry 2011;72: 1577-1584.
66. Martins JG: EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr 2009; 28:525-542.
67. Rondanelli M, Giacosa A, Opizzi A, Pelucchi C, La Vecchia C, Montorfano G, Negroni M, Berra B, Politi P, Rizzo AM: Long chain omega 3 polyunsaturated fatty acids supplementation in the treatment of elderly depression: effects on depressive symptoms, on phospholipids fatty acids profile and on health-related quality of life. J Nutr Health Aging 2011;15:37-44.
68. Hamazaki K, Choi KH, Kim HY: Phospholipid profile in the postmortem hippocampus of patients with schizophrenia and bipolar disorder: no changes in docosahexaenoic acid species. J Psychiatr Res 2010;44:688-693.
69. Balanzá-Martínez V, Fries GR, Colpo GD, et al: Therapeutic use of omega-3 fatty acids in bipolar disorder. Expert Rev Neurother 2011;11:1029-1047.
70. Osher Y, Bersudsky Y, Belmaker RH: Omega-3 eicosapentaenoic acid in bipolar depression: report of a small openlabel study. J Clin Psychiatry 2005;66: 726-729.
71. Keck PE Jr, Mintz J, McElroy SL, Freeman MP, et al: Double-blind, randomized, placebo-controlled trials of ethyleicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 2006; 60:1020-1022.
72. Evans SJ, Prossin AR, Harrington GJ, Kamali M, Ellingrod VL, Burant CF, McInnis MG: Fats and factors: lipid profiles associate with personality factors and suicidal history in bipolar subjects. PLoS One 2012;7:e29297.
73. Clayton EH, Hanstock TL, Hirneth SJ, Kable CJ, et al: Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation. Eur J Clin Nutr 2009;63:1037-1040.
74. Dinan T, Siggins L, Scully P, O'Brien S, et al: Investigating the inflammatory phenotype of major depression: focus on cytokines and polyunsaturated fatty acids. J Psychiatr Res 2009;43:471-476.
75. Jazayeri S, Keshavarz SA, Tehrani-Doost M, Djalali M, et al: Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder. Psychiatry Res 2010;178:112-115.
76. Kiecolt-Glaser JK, Belury MA, Porter K, Beversdorf DQ, et al: Depressive symptoms, omega-6:omega-3 fatty acids, and inflammation in older adults. Psychosom Med 2007;69:217-224.
77. Kiecolt-Glaser JK, Belury MA, Andridge R, et al: Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial. Brain Behav Immun 2011;25:1725-1734.